“Someone turned the R&D lights on for big pharma except we are there first... hopefully with patents in hand...or maybe these are a couple of the suitors??”

Based on the PR, these suitors have already chosen their COVID cocktail and leronlimab is not part of that cocktail. I mentioned this recently: NP once said he turned down an offer to combine leronlimab in a trial with another treatment. I always thought he was referring to remdesevir but maybe it was for a different cocktail.

I can’t understand how BP wouldn’t identify leronlimab as a potential cocktail ingredient given the MOA, HIV results. eIND results, M2M results Nd safety profile. Just doesn’t make much scientific sense.